OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Tokenizing loops of antibodies	260
Correction	165
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	161
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	141
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	139
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	129
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	94
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	92
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	90
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	89
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	86
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	80
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	68
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	66
An antibody developability triaging pipeline exploiting protein language models	61
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	60
Correction	55
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	55
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	51
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	51
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	50
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	48
Impact of IgG subclass on monoclonal antibody developability	45
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	45
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates	44

Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	43
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	43
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	40
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	38
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	38
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	37
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	35
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	34
Antibodies to watch in 2024	34